PEDIATRIC ONCOLOGY GROUP

儿科肿瘤组

• 批准号: 2856231
• 负责人: V M WHITEHEAD
• 金额: $ 8.65万
• 依托单位: MONTREAL CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-01-01 至 2000-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2856231
• 关键词: 6 thiopurine; Ewing's tumor; Hodgkin's disease; Wilms' tumor; XomaZyme; acivicin; acute leukemia; acute lymphocytic leukemia; acute myelogenous leukemia; adolescence (12-20); antineoplastics; asparaginase; astrocytoma; biological response modifiers; bone marrow transplantation; brain neoplasms; cancer registry /resource; cancer risk; central nervous system neoplasms; child (0-11); chronic myelogenous leukemia; cis platinum compound; clinical research; clinical trial phase I; colony stimulating factor; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; cyclosporines; cytosine arabinoside; daunorubicin; deferoxamine; deoxycoformycin; doxorubicin; drug screening /evaluation; enalapril; ependymoma; etoposide; fazarabine; fluorouracil; germ cell neoplasms; glioma; hepatoblastoma; hepatocellular carcinoma; human genetic material tag; human immunodeficiency virus 1; human subject; human therapy evaluation; human tissue; ifosfamide; interferons; interleukin 2; medulloblastoma; melphalan; metastasis; methotrexate; mitoxantrone; molecular oncology; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer surgery; neuroblastoma; nonHodgkin's lymphoma; osteosarcoma; paclitaxel; pediatric pharmacology; podophyllin; prednisone; retinoate; rhabdomyosarcoma; tissue resource /registry; topotecan; trimetrexate; vincristine

The Pediatric Oncology Group (POG) is a multi-disciplinary, multi- institutional research community which collaborates to increase knowledge of and improve treatment for cancer and leukemia in children and adolescents. The Montreal Children's Hospital/McGill University (MCH), a founding member, requests funding for itself and its two affiliates, the Children's Hospital of Eastern Ontario (CHEO) and the University of Sherbrooke Medical Center (USMC) to continue to participate fully in administrative and scientific activities of the POG during the next 5 years. We expect to enroll a total of 70 patients a year on therapeutic protocols for childhood leukemias, lymphomas, solid tumors and brain tumors, with continued emphasis on Phase I and II studies of new agents and coordination or co-coordination of a minimum of 13 protocols. We expect to enroll 110 patients per year on non-therapeutic studies of cancer etiology, epidemiology, biology, psychologic impact and late effects of therapy with particular emphasis on the pharmacology and molecular pharmacology of methotrexate in acute lymphoblastic leukemia (ALL). We will comply with all requirements of the POG constitution, with MR regulations governing ethical conduct of clinical research and with OPRR and IRB requirements for informed consent and protection of subjects from research risks. In addition to an anticipated doubling of patient accruals since 5 years ago, our major contributions to POG research will include: confirmation that the extent of accumulation of methotrexate polyglutamates by lymphoblasts in B-progenitor cell ALL correlates with event-free survival (EFS) and characterization of the mechanisms regulating this metabolism (Whitehead); promotion of new agent drug development through New Agents and Pharmacology Committee leadership (Whitehead and Bernstein) and protocol coordination (Bernstein, Baruchel); introduction of stereotactic and fractionated stereotactic radiation therapy in brain tumors (Freeman); coordination of treatment protocols of newly-diagnosed and relapsed B-progenitor cell ALL (Abish, Bernstein); introduction of new agents and combinations in recurrent lymphoid disease as Sub-committee Chair, Lymphoid Relapse (Bernstein); chemotherapy and surgery of brain tumors (Baruchel, Ventureyra); and study of the biology, including p53 gene mutations, and treatment of HIV-related lymphomas (Baruchel, Whitehead).

儿科肿瘤组（POG）是一个多学科，多学科， 机构研究社区，合作以增加知识 改善儿童癌症和白血病的治疗， 青少年。蒙特利尔儿童医院/麦吉尔大学（MCH），a 为自己及其两个附属机构， 东安大略儿童医院和安大略大学 舍布鲁克医疗中心（USMC）将继续全面参与 未来5年POG的行政和科学活动 年我们预计每年总共招募70名患者接受治疗， 儿童白血病、淋巴瘤、实体瘤和脑 肿瘤，继续强调新药物的I期和II期研究 以及至少13项议定书的协调或共同协调。我们 预计每年招募110名患者进行非治疗性研究， 癌症病因学、流行病学、生物学、心理影响和晚期 治疗效果，特别强调药理学和 甲氨蝶呤治疗急性淋巴细胞白血病的分子药理学 （全部）。我们将遵守POG章程的所有要求， 管理临床研究伦理行为的MR法规， OPRR和IRB对知情同意和受试者保护的要求 研究风险。 除了预期自5年以来患者应计费用增加一倍外， 前，我们对POG研究的主要贡献将包括： 甲氨蝶呤聚谷氨酸盐的蓄积程度 B祖细胞ALL中的淋巴母细胞与无事件生存相关 (EFS)以及调节这种代谢的机制的表征 （Whitehead）;通过新药促进新药开发 和药理学委员会领导层（Whitehead和伯恩斯坦），以及 协议协调（伯恩斯坦，Baruchel）;引入立体定向 脑肿瘤的立体定向放射治疗 （弗里曼）;协调新诊断和 复发性B祖细胞ALL（Abish，伯恩斯坦）;引入新的 复发性淋巴样疾病的药物和联合治疗小组委员会 椅子，类风湿性关节炎复发（伯恩斯坦）;化疗和脑外科手术 肿瘤（Baruchel，Ventureyra）;以及生物学研究，包括p53 基因突变和HIV相关淋巴瘤的治疗（Baruchel， Whitehead）。